Acurx Pharmaceuticals (ACXP) Q3 2026 earnings summary

Executive summary

• PATHFINDER, a 20-patient trial in multiply recurrent CDI, began enrollment September 29, ahead of the original Q4 2026 expectation; findings are intended to guide Phase 3 planning.

• FDA is open to discussing the totality of PATHFINDER and IBZ-ASPIRE efficacy evidence at a pre-NDA meeting, assessing whether it can support an NDA.

• Q3 net loss was $2.58 million and cash was $9.65 million at September 30, 2026; available cash is not expected to cover the next 12 months’ anticipated needs.

Financial highlights

• Q3 R&D expense was $1.12 million vs. $0.43 million YoY; 9M expense was $2.53 million vs. $1.55 million, primarily reflecting recurrent CDI program costs.

• Q3 G&A expense was $1.52 million vs. $1.60 million YoY; 9M G&A was $4.13 million vs. $4.92 million, mainly due to lower professional fees and legal costs.

• Q3 operating expenses and operating loss were $2.63 million vs. $2.03 million; net loss was $2.58 million vs. $1.99 million.

• 9M operating expenses and operating loss were $6.65 million vs. $6.47 million; net loss was $6.52 million vs. $6.39 million.

• Cash was $9.65 million at September 30, 2026, vs. $7.6 million at December 31, 2025.

Outlook and guidance

• FDA review of PATHFINDER and IBZ-ASPIRE will assess whether combined efficacy evidence is robust enough to support an NDA; a pre-NDA discussion may follow completion of trial data.

• PATHFINDER II under the LPAD pathway may be an alternative to ASPIRE; if PATHFINDER succeeds, its results with IBZ-ASPIRE could support potential acute and recurrence-prevention indications.

• PATHFINDER II could enroll ~350 patients internationally over 1.5–2 years with an active comparator; VOWST is under consideration, and design and cost depend on PATHFINDER results.

• Trial enrollment completion and a data update are anticipated in H2 2027, depending on enrollment pace; progression to PATHFINDER II depends on FDA review of the 20-patient data.

• Ibezapolstat is Phase 3-ready for acute CDI, subject to financing; R&D spending is expected to increase substantially as development advances.